Clinical characteristics, treatment and prognosis of ixekizumab-induced inflammatory bowel disease

Background： To explore the clinical characteristics of ixekizumab-induced inflammatory bowel disease (IBD) and provide references for prevention, diagnosis and treatment.Methods： Clinical reports of ixekizumab-induced IBD published on December 31, 2025 were collected for retrospective analysis.Results： A total of 30 patients were enrolled, with a median age of 47.5 years (range 21, 81). The median time of IBD onset was 4 months (range 0.25, 24). Abdominal pain (80.0%), diarrhea (56.7%), hematochezia (30.0%), bloody diarrhea (26.7%), weight loss (26.7%), and fever (23.3%) were the main symptoms. Colonoscopy can reveal ulcers (80.0%), loss of vascular pattern (26.7%), erythema (26.7%), friability (26.7%), colitis (23.3%), and bleeding (20.0%). After discontinuing ixekizumab and receiving systemic steroids (70.0%), anti-TNF therapy (53.3%), and mesalazine treatment, most patients experienced symptom improvement.Conclusion： Ixekizumab was associated with exacerbation or new-onset IBD within the first six months. Gastrointestinal symptoms and a family history of IBD should be ruled out before ixekizumab is administered. During the treatment with ixekizumab, the patient's gastrointestinal symptoms should be closely monitored.